Testosterone and atherosclerosis — is there any relationship?
Kashtalap V. V.1,2, Khryachkova O. N.1, Shibanova I. A.1, Barbarash O. L.1,2
1 Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo
2 Kemerovo State Medical University
Atherosclerosis is a common and socially significant disease, and the main cause of morbidity, disability and mortality in the industrialized world. For men, the role of the main sex hormone — testosterone in the pathogenesis of atherosclerosis and its complications remains insufficiently studied. The mechanism of atherogenesis is complex and involves a lot of interacting complex factors, both internal and external. There is an opinion, that there are gender differences in the atherogenesis mechanisms in men and women, caused by the biological effects of the hormones. The review, based on the results of experimental and clinical studies, highlights current ideas about the relationship between testosterone levels and cardiovascular health, aging, the formation of atherosclerosis, and current ideas about the effects of hormone replacement therapy in men. To compile a review article, available materials from foreign library databases (Library’s MEDLINE / PubMed database) were used.
Key words: testosterone, atherosclerosis, aging, hormone replacement therapy, myocardial infarction, ischemic stroke.
For citation: Kashtalap V.V., Khryachkova O.N., Shibanova I.A., Barbarash O.L. Testosterone and atherosclerosis — is there any relationship? // RMJ. Medical Review. 2018. № 4. P. 4–7.
References
1. Барбараш Л. С., Кашталап В. В., Зыков М. В. и др. Распространенность и клиническая значимость мультифокального атеросклероза у пациентов с инфарктом миокарда и подъемом сегмента ST // Кардиология и сердечно-сосудистая хирургия. 2010. № 3 (5). С.31–36 [Barbarash L.S., Kashtalap V. V., Zykov M. V. i dr. Rasprostranennost i klinicheskaya znachimost multifokalnogo ateroskleroza u pacientov s infarktom miokarda i podemom segmenta ST // Kardiologiya i serdechno-sosudistaya hirurgiya. 2010. № 3 (5). S.31–36 (in Russian)].
2. Lopez A. D., Murray C. C. The global burden of disease, 1990–2020 // Nat Med. 1998. Vol. 4. P.1241–1243.
3. Rosengren A., Wallentin L., Gitt K. A. Sex, age and clinical presentation of acute coronary syndromes // Eur. Heart. J. 2004. Vol. 25. P.663–667.
4. Mikkola T. S., Tuomikoski P., Lyytinen H. et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality // Menopause. 2015. Vol. 22 (9). P.976–983. doi: 10.1097/GME.0000000000000450
5. Jones T. H. Testosterone deficiency: a risk factor for cardiovascular disease? // Trends Endocrinol Metab. 2010. Vol. 21. P.496–503.
6. Mendelsohn M. E., Karas R. H. Molecular and cellular basis of cardiovascular gender differences // Science. 2005. Vol. 308 (5728). P.158–1587.
7. Daniel K. M., Jones T. H. Testosterone and Cardiovascular Risk in Men. Granata R, Isgaard J (eds): Cardiovascular Issues in Endocrinology // Front Horm Res. Basel, Karger. 2014. Vol. 43. P.1–20. doi: 10.1159/000360553
8. Fahed A. C., Gholmieh J. M., Azar S. T. Connecting the Lines between Hypogonadism and Atherosclerosis. International Journal of Endocrinology. 2012. Article ID 793953. 12 p. doi:10.1155/2012/793953
9. Jackenhovel F. Male Hypogonadism. Auflage-Bremen: Uni-Med. 2004. 185 p.
10. Yeap B. B. Androgens and cardiovascular disease // Curr Opin Endocrinol Diabetes Obes. 2010. Vol. 17. P.269–276.
11. Gorbachinsky I. Metabolic Syndrome and Urological Diseases // Rev Urol. 2010. Vol. 12 (4). P.157–180.
12. Тюзиков И. А., Калинченко С. Ю. Андрогенный дефицит в общей врачебной практике: эндокринология, рациональная диагностика и клинические маски // Медицинский алфавит. Больница — вся для ЛПУ. 2012. № 1. С.13–19 [Tyuzikov I.A., Kalinchenko S. Yu. Androgennyy deficit v obschey vrachebnoy praktike: endokrinologiya, racionalnaya diagnostika i klinicheskie maski // Medicinskiy alfavit. Bolnica — vsya dlya LPU. 2012. № 1. S.13–19 (in Russian)].
13. Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men // Aging Male. 2015. Vol. 18 (1). P.5–15.
14. Liverman C. T., Blazers D. G. Testosterone and aging: clinical research directions. The National academies of press. Washington, D.C. 2004. 219 p.
15. Vlachopoulos C., Pietri P., Ioakeimidis N. et al. Inverse association of total testosterone with central haemodynamics and left ventricular mass in hypertensive men // Atherosclerosis. 2016. Vol. 250. P.57–62 doi: 10.1016/j.atherosclerosis.2016.04.018
16. Webb C. M., McNeill J.G., Hayward C. S. et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease // Circulation. 1999. Vol. 100. P.1690–1696.
17. Deenadayalu V. P., White R. E., Stallone J. N. et al. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel // Am. J. Physiol. Heart Circ. Physiol. 2001. Vol. 281. P.1720–H1727.
18. English K. M., Jones R. D., Jones T. H. et al. Testosterone acts as a coronary vasodilator by a calcium channel antagonist action // J. Endocrinol. Invest. 2002. Vol. 25. P.455–458.
19. Yeap B. B., Chubb S. A., Hyde Z. et al. Low serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health in Men Study // Eur. J. Endocrinol. 2009. Vol. 161. P.591–598.
20. Barrett-Connor E., Khaw K. T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study // Circulation. 1988. Vol. 78. P. 539–545.
21. Torkler S., Wallaschofski H., Baumeister S. et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure // Aging Male. 2011. Vol. 14. P. 176–182.
22. Schipf S., Haring R., Friedrich N. et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP) // Aging Male. 2011. Vol. 14. P.168–175.
23. Kalyani R. R., Dobs A. S. Androgen deficiency, diabetes, and the metabolic syndrome in men // Curr Opin Endocrinol Diabetes Obes. 2007. Vol. 14. P.226–234. doi: 10.1097/MED.0b013e32814db856
24. Firtser R., Juonala M., Magnussen C. G. et al. Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24–45 years. The Cardiovascular Risk in Young Finns Study // Atherosclerosis. 2012. Vol. 222. P.257–262.
25. Golovkin A. S., Kokov A. N., Masenko V. et al. Markers of calcium and phosphate metabolism and osteopenic syndrome in patients with coronary artery disease // Panminerva Med. 2016. Vol. 58 (4). P.253–262.
26. Кашталап В. В., Хрячкова О. Н., Барбараш О. Л. «Новый» патологический континуум: гипогонадизм, остеопороз и кальцинирующий атеросклероз. Общие факторы формирования и прогрессирования // Атеросклероз. 2016. Т.12. № 4. С.68–78 [Kashtalap V.V., Hryachkova O. N., Barbarash O. L. «Novyy» patologicheskiy kontinuum: gipogonadizm, osteoporoz i kalciniruyuschiy ateroskleroz. Obschie faktory formirovaniya i progressirovaniya // Ateroskleroz. 2016. T.12. № 4. S.68–78 (in Russian)].
27. Rabkin G. G., Wagner G. J., Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symtoms // Archives of General Psychiatry. 2000. Vol. 57 (2). P.141–147.
28. Сумин А. Н. Поведенческий тип личности Д (дистрессорный) при сердечно-сосудистых заболеваниях // Кардиология. 2010. № 50 (10). С.66–73 [Sumin A. N. Povedencheskiy tip lichnosti D (distressornyy) pri serdechno-sosudistyh zabolevaniyah // Kardiologiya. 2010. № 50 (10). S.66–73 (in Russian)].
29. Srinath R., Gottesman R. F., Golden H. S. et al. Association Between Endogenous Testosterone and Cerebrovascular Disease in the ARIC Study (Atherosclerosis Risk in Communities). // Stroke. 2016. Vol. 47 (11). P.2682–2688.
30. Wang X., Magkos F., Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it’s not just about sex hormones // J Clin Endocrinol Metab. 2011. Vol. 96. P.885–893. doi: 10.1210/jc.2010–2061
31. Abbott R. D., Launer L. J., Rodriguez B. L. et al. Serum estradiol and risk of stroke in elderly men // Neurology. 2007. Vol. 68. P.563–568. doi: 10.1212/01.wnl.0000254473.88647.ca
32. Arnlöv J., Pencina M. J., Amin S. et al. Endogenous sex hormones and cardiovascular disease incidence in men // Ann Intern Med. 2006. Vol. 145. P.176–184.
33. Shores M. M., Biggs M. L., Arnold A. M. et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study // J Clin Endocrinol Metab. 2014. Vol. 99. P.2061–2068. doi: 10.1210/ jc.2013–3576
34. Yeap B. B., Alfonso H., Chubb S. A. et al. In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction // J Clin Endocrinol Metab. 2014. Vol. 99. P. 4565–4573. doi: 10.1210/jc.2014–2664
35. Holmegard H. N., Nordestgaard B. G., Jensen G. B. et al. Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses // J Clin Endocrinol Metab. 2015. 20152687.
36. Zhao J. V., Schooling C. M. Endogenous androgen exposures and ischemic heart disease, a separate sample Mendelian randomization study // Int J Cardiol. 2016. Vol. 222. P.940–945. doi: 10.1016/j.ijcard.2016.07.174
37. Soisson V., Brailly-Tabard S., Helmer C. et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study // Maturitas. 2013. Vol. 75. P.282–288. doi: 10.1016/j.maturitas.2013.04.012
38. Jones H. T., Arver S., Behre H. et al. and TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study) // Diabetes Care. 2011. Vol. 34. P.828–837.
39. Mårin P., Holmang S., Gustafsson C. et al. Androgen treatment of abnormally obese men // Obes. Res. 1993. Vol. 1. P.245–251.
40. Naftolin F., Mehr H., Fadiel A. Sex Steroids Block the Initiation of Atherosclerosis // Reproductive Sciences. 2016. Vol. 23 (12). P.1620–1625.
41. Sharma R., Oni O., Gupta K. et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men // Eur. Heart J. 2015. Vol. 36. P.2706–2715.
42. Basaria S., Coviello A., Travison T. et al. Adverse events associated with testosterone administration // N. Engl. J. Med. 2010. Vol. 363. P.109–122.
43. Alexander G. C., Iyer G., Lucas E. et al. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis // Am J Med. 2016. pii: S0002–9343 (16) 31024–5. doi: 10.1016/j.amjmed.2016.09.017
44. Ramasamy R., Scovell J., Mederos M. et al. Association between testosterone supplementation therapy and thrombotic events in elderly men // Urology. 2015. Vol. 86. P.283–286.
45. Shores M. M., Smith N. L., Forsberg C. W. et al. Testosterone treatment and mortality in men with low testosterone levels // J Clin Endocrinol Metab. 2012. Vol. 97. P.2050–2058.
46. Vigen R., O’Donnell C., Barón A. E. et al. Association of testosterone therapy with mortality, myocardialInfarction, and stroke in men with low testosterone levels // JAMA. 2013. Vol. 310 (17). P.1829–1836. doi:10.1001/jama.2013.280386
47. Finkle W. D., Greenland S., Ridgeway G. K. Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men // PLoS One. 2014. Vol. 9. E85805.
48. Cheetham T. C., An J. J., Jacobsen S. J. et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency // JAMA Internal Medicine. 2017. E1–E9. doi:10.1001/jamainternmed.2016.9546
49. Snyder P. J., Ellenberg S. S., Cunningham G. R. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men // Clin Trials. 2014. Vol. 11. P.362–375.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
